AUPH Stock News & Catalysts – Aurinia Pharmaceuticals

FEATURED

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on recent business progress. Financial Results Total

Summary

Oct 30, 2026, 8:00 AM ·Business Wire

RECENT

Aurinia Settles Patent Litigation with Teva

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, "Aurinia") have entered into a settlement agreement with Teva Pharmaceuticals

Aug 19, 2026, 4:05 PM ·Business Wire

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three and six months ended June 30, 2026 and provided an update on recent business progress. Financial Results Total Revenue:

Aug 6, 2026, 8:00 AM ·Business Wire

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

— Multitarget Approach Has Potential to Further Improve Outcomes in This Disease Characterized by Continued Unmet Need — Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced the initiation of PRESERVE, a Phase

Jul 6, 2026, 8:00 AM ·Business Wire

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

— New Analysis of the AURORA 1 Phase 3 Study Presented at EULAR 2026 Congress — Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS® in the

Jun 4, 2026, 7:00 AM ·Business Wire

TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.

SAN DIEGO, June 3, 2026 /CNW/ - Tang Capital Management, LLC announces that on June 2, 2026, it acquired 206,005 common shares (the "Common Shares") of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (the

Jun 3, 2026, 12:43 AM ·PRNewswire

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three months ended March 31, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the

May 7, 2026, 8:00 AM ·Business Wire

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a

Mar 30, 2026, 8:00 AM ·Business Wire

MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition

Believes the Board's Decision to Remove CEO Peter Greenleaf and Install Kevin Tang as CEO Validates Multi-Year Shareholder Campaign Commends New Leadership's Commitment to Shareholder Alignment Through Zero CEO

Mar 23, 2026, 11:00 AM ·Business Wire

Aurinia Announces Management Transition

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced today that Kevin Tang, Aurinia's Chair of the Board, will succeed Peter Greenleaf as Chief Executive Officer. Peter will continue as a consultant to facilitate the

Mar 23, 2026, 8:00 AM ·Business Wire

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

Full Year 2025 LUPKYNIS Sales Grew 25% Announces LUPKYNIS Sales Guidance for 2026 of $305 Million to $315 Million Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three and twelve

Feb 26, 2026, 6:00 AM ·Business Wire

Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it will report financial results for the three and twelve months ended December 31, 2025, and provide an update on recent business progress on February 26,

Feb 19, 2026, 6:00 AM ·Business Wire

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

Third Quarter 2025 LUPKYNIS Sales Grew 27% LUPKYNIS Sales Guidance for 2025 Raised to $265 Million to $270 Million Aritinercept Advances Toward Clinical Studies in Two Autoimmune Diseases Aurinia Pharmaceuticals Inc.

Nov 4, 2025, 6:00 AM ·Business Wire

Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it will report financial results for the three and nine months ended September 30, 2025, and provide an update on recent business progress on November 4,

Nov 3, 2025, 6:00 AM ·Business Wire

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS® (voclosporin) at the American

Oct 15, 2025, 6:00 AM ·Business Wire

Aurinia Pharmaceuticals Inc. AUPH · News